Alpha Cognition Reaches Licensing Agreement in China
Alpha Cognition, a biopharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, has entered into an exclusive licensing agreement with China Medical System Holdings Limited (CMS). CMS is a leading platform company specializing in pharmaceutical innovation, commercialization, and comprehensive product lifecycle management in the People’s Republic of China. The agreement grants CMS the rights to develop, manufacture, and commercialize ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia, and New Zealand. ZUNVEYL, a next-generation acetylcholinesterase inhibitor, is approved in the United States for treating mild-to-moderate Alzheimer’s disease.
Alpha Cognition Reaches Licensing Agreement in China